# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001104659-25-058887
**Filing Date:** 2025-6
**Character Count:** 8604
**Document Hash:** 1c20eb86868eb24ef8aaeeb51b0eb03d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-058887.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001104659-25-058887

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250611

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37467
- **FILM NUMBER:** 251042756

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 11, 2025**

**Astria Therapeutics, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37467** | **26-3687168** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **22 Boston Wharf Road**<br> **10th Floor** |  |
| **Boston** **, Massachusetts** | **02210** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

Registrant's telephone number, including area code: **(617) 349-1971**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading <br> Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.001 per share** | **ATXS** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On June 11, 2025, Astria Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders, upon the recommendation of the Company's Board of Directors, approved the first amendment to the Company's Second Amended and Restated 2015 Stock Incentive Plan, (the "Second Amended and Restated 2015 Plan"), which amendment had been previously approved by the Company's Board of Directors subject to stockholder approval, to increase the number of shares of the Company's common stock that may be issued under the Second Amended and Restated 2015 Plan by 5,500,000 shares.

The description of the Second Amended and Restated 2015 Plan contained in the Company's [proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 28, 2025 (the "Proxy Statement](https://www.sec.gov/ix?doc=/Archives/edgar/data/1454789/000110465925040180/tm252430-2_def14a.htm)"), under the heading "Proposal No. 2—Approval of the first amendment to the Second Amended and Restated 2015 Plan" is incorporated herein by reference. A complete copy of the first amendment to the Second Amended and Restated 2015 Plan is attached as [Appendix A to the Proxy Statement](https://www.sec.gov/Archives/edgar/data/1454789/000110465925040180/tm252430-2_def14a.htm#tAPA) and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 11, 2025, the Company held the Annual Meeting. The following is a summary of the matters voted on at the Annual Meeting.

a) <u>Proposal 1</u>. The stockholders of the Company elected Jill C. Milne, Fred Callori, and Michael Kishbauch as Class I directors
to the Company's Board of Directors, each to serve for a three-year term expiring at the annual meeting of stockholders to be held
in 2028. The results of the stockholders' vote with respect to the election of Class I directors were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Votes For** | **Votes For** | **Votes Withheld** | **Votes Withheld** | **Broker Non-<br> Votes** | **Broker Non-<br> Votes** | **Votes Abstaining** |
| **Jill C. Milne** |  | 49955122 |  | 200160 |  | 3401529 |  |
| **Fred Callori** |  | 43513443 |  | 6641839 |  | 3401529 |  |
| **Michael Kishbauch** |  | 42381788 |  | 7773494 |  | 3401529 |  |

---

b) <u>Proposal 2</u>. The stockholders of the Company approved the first amendment to the Second Amended and Restated 2015 Plan to increase
the number of shares of common stock available for grant under the plan by five million, five hundred thousand (5,500,000) shares. The
results of the stockholders' vote with respect to the approval of the first amendment to the Second Amended and Restated 2015 Plan
were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Against** | **Broker Non-Votes** | **Broker Non-Votes** | **Votes Abstaining** | **Votes Abstaining** |
| 42460419 |  | 7684293 |  | 3401529 |  | 10570 |

---

d) <u>Proposal 3</u>. The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company's independent
registered public accounting firm for the fiscal year ending December 31, 2025. The results of the stockholders' vote with
respect to the ratification of such appointment were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Against** | **Broker Non-Votes** | **Votes Abstaining** | **Votes Abstaining** |
| 53498117 |  | 53293 |  |  | 5401 |

---

e) <u>Proposal 4</u>. The stockholders of the Company approved, on an advisory basis, the compensation
 of the Company's named executive officers. The results of the stockholders' vote with respect to the
advisory vote on executive compensation were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Against** | **Broker Non-Votes** | **Broker Non-Votes** | **Votes Abstaining** | **Votes Abstaining** |
| 43538692 |  | 6611451 |  | 3401529 |  | 5139 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ASTRIA THERAPEUTICS, INC.** | **ASTRIA THERAPEUTICS, INC.** |
| Date: June 12, 2025 | By: | /s/ Ben Harshbarger |
|  |  | Ben Harshbarger |
|  |  | Chief Legal Officer |

---